| 产品详情 |
| Edit |   |
|---|
| Product Name | Iniparib (BSI-201) |
|---|
| Description | MW: 292.03. Background: BSI-201 (Iniparib, SAR240550) is a PARP1 inhibitor.In vitroBSI-201 is described as a prodrug of 4-iodo-3-nitrosobenzamide, an agent that covalently inhibits PARP1 by binding to its first zinc finger under cell-free conditions. Treatment of 120 uM BSI-201 plus buthionine sulfoximine (BSO) induces a 95% cell death among 855-2 cells, and displays a similar effect in other human cancer cells. BSI-201 inhibits the growth of E-ras 20 cells, the effect of which ca |
|---|
| Size | 10 mg |
|---|
| Concentration | n/a |
|---|
| Applications | n/a |
|---|
| Other Names | n/a |
|---|
| Gene, Accession, CAS # | n/a |
|---|
| Catalog # | MBS8506573 |
|---|
| Price | |
|---|
| Order / More Info | Iniparib (BSI-201) from MYBIOSOURCE INC. |
|---|
| Product Specific References | [1] Cancer Biology & Therapy 1 January 2009;8:1, 2-3 [2] Acta Pharmacologica Sinica 2010;31: 1172 -1180; [3] Neuroscience 2010;171:1256 -1264 [4] Mendeleyev J, et al. Biochem Pharmacol, 1995, 50(5), 705-714. [5] Bauer PI, et al. Biochem Pharmacol, 2002, 63(3), 455-462. [6] Liu X, et al. Clin Cancer Res, 2012, 18(2), 510-523. [7] Ma W, et al. Proc Natl Acad Sci U S A, 2012, 109(17), 6590-6595. [8] Patel AG, et al. Clin Cancer Res, 2012, 18(6), 1655-1662. The pharmacological and toxicological prop |
|---|
| 产品资料 |
|
|